By this principle, the blockade of PD-1/PD-L1 interaction by monoclonal antibodies against either PD-1 (pembrolizumab and nivolumab) or PD-L1 (durvalumab, atezolizumab, and avelumab) appears to be a logical therapeutic strategy, particularly for a highly antigenic solid tumor, including GC [10,21]. This evidence concerns the gene CD274 and gastric cancer.